Completed PHASE2 INTERVENTIONAL 1-arm NCT00520936

A Study of Pemetrexed in Children With Recurrent Cancer

A Phase II Study of Pemetrexed in Children With Recurrent Malignancies

Sponsor: Children's Oncology Group

Conditions Ependymoma Medulloblastoma Neuroblastoma (Measurable Disease) Neuroblastoma (Metaiodobenzylguanidine Non-brainstem High-grade Glioma Osteosarcoma Positive Evaluable) Rhabdomyosarcoma Sarcoma, Ewing's

Interventions pemetrexed

Updated 6 times since 2017 Last updated: Feb 23, 2011 Started: Sep 30, 2007 Primary completion: Feb 28, 2010 Completion: Feb 28, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Ependymoma and Medulloblastoma, this trial is completed. The trial is conducted by Children's Oncology Group and has accumulated 6 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Children's Oncology Group
Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Arcadia, United States